SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharma - Quaterly Results

26 Oct 2021 Evaluate
The company witnessed a 16.48% growth in the revenue at Rs. 355.08 millions for the quarter ended September 2021 as compared to Rs. 304.85 millions during the year-ago period.The company has announced a 40.54% increase in its profits to Rs . 79.70  millions for the  quarter ended September 2021 compared to Rs. 56.71 millions in the corresponding quarter in the previous year.OP of the company witnessed a marginal growth to 114.59 millions from 81.93 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 355.08 304.85 16.48 626.88 479.16 30.83 1092.94 1188.91 -8.07
Other Income 11.91 10.23 16.42 23.86 19.99 19.36 43.08 42.18 2.13
PBIDT 114.59 81.93 39.86 180.14 97.96 83.89 241.52 239.63 0.79
Interest 1.09 1.24 -12.10 2.12 2.36 -10.17 4.74 5.26 -9.89
PBDT 113.50 80.69 40.66 178.02 95.60 86.21 236.78 234.37 1.03
Depreciation 4.54 5.06 -10.28 8.88 10.00 -11.20 20.35 22.99 -11.48
PBT 108.96 75.63 44.07 169.14 85.60 97.59 216.43 211.38 2.39
TAX 29.26 18.92 54.65 42.93 18.81 128.23 51.39 62.68 -18.01
Deferred Tax -0.74 -1.08 -31.48 -1.35 -5.04 -73.21 -3.91 3.69 -205.96
PAT 79.70 56.71 40.54 126.21 66.79 88.97 165.04 148.70 10.99
Equity 45.89 45.89 0.00 45.89 45.89 0.00 45.89 45.89 0.00
PBIDTM(%) 32.27 26.88 20.08 28.74 20.44 40.56 22.10 20.16 9.64

Jenburkt Pharma Share Price

1025.60 6.35 (0.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×